DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the ...

DexCom is expected to announce its second-quarter earnings soon, and Wall Street expects the company’s EPS to increase by a ...

DexCom (DXCM) faces GLP-1 disruption as it targets non-insulin Type 2 CGM growth. Read here for a detailed invesment analysis ...

Shares of DexCom Inc. DXCM advanced 3.47% to $71.25 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX remaining mostly unchanged at 7, ...

Smartwatches still can’t measure blood sugar on their own, but AI-powered CGMs are changing how glucose data is tracked and ...

Shares of DexCom Inc. DXCM slipped 3.76% to $67.35 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.79% to 7,499.36 and ...

AI may help smartwatches make glucose data more useful through better predictions, pattern detection, and personalized health ...

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights: Revenue ...

FDA clears Dexcom Stelo as the first OTC CGM for children, raising new questions around app access, caregiver oversight, school device rules, and reimbursement.

Dexcom anticipates that the findings could drive a shift in the standard of care for type 2 diabetes patients who do not use ...

Compare the best Samsung Watch CGM apps and Wear OS tools for blood sugar readings, including Dexcom G6, Gluroo, and xDrip+.

Following expanded FDA approval for pediatric patients, the over-the-counter Stelo continuous glucose monitor is adding AI ...